Schuchter et al developed a prognostic model for predicting 10 year survival in patients with primary cutaneous malignant melanoma. This can help identify patients at risk for recurrence for whom adjuvant therapy may be beneficial. The authors are from the University of Pennsylvania, The Lombardi Cancer Center, and Beth Israel Hospital.